Physician profile
Paul E Morin
NPI 1932148525
$1,328.34
in general payments reported to CMS, 2019-2025
16 companies · $268 in 2025
The $268 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $280 · 2020: $380 · 2021: $132 · 2022: $11.74 · 2023: $154 · 2024: $102 · 2025: $268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $524.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $524.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $432.81 | 2021-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $246.02 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $167.95 | 2019-2023 | Trintellix |
| Lilly USA, LLC | $120.79 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.26 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $67.35 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $42.48 | 2019-2021 | |
| Gilead Sciences, INC. | $35.72 | 2019-2020 | |
| Genentech USA, INC. | $24.28 | 2020 | |
| Eisai INC. | $18.75 | 2020 | |
| Stryker Corporation | $17.95 | 2021 | |
| Vertiflex, INC. | $17.70 | 2019 | |
| Pfizer INC. | $16.83 | 2021 | |
| Jazz Pharmaceuticals INC. | $16.72 | 2020 | |
| Therapeuticsmd, INC. | $13.99 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $11.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Morin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.